Cargando…

Innovative Analyses Support a Role for DNA Damage and an Aberrant Cell Cycle in Myelodysplastic Syndrome Pathogenesis

We used flow cytometry to analyze the cell cycle, DNA damage, and apoptosis in hematopoietic subsets in MDS marrow. Subsets were assigned using CD45, side scatter, CD34, and CD71. Cell cycle fractions were analyzed using DRAQ 5 (DNA content) and MPM-2 (mitoses). DNA damage was assessed using p-H2A.X...

Descripción completa

Detalles Bibliográficos
Autores principales: Head, David R., Jacobberger, James W., Mosse, Claudio, Jagasia, Madan, Dupont, William, Goodman, Stacey, Flye, Leanne, Shinar, Andrew, McClintock-Treep, Sara, Stelzer, Greg, Briggs, Robert, Shults, Keith
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3200066/
https://www.ncbi.nlm.nih.gov/pubmed/22046573
http://dx.doi.org/10.1155/2011/950934
_version_ 1782214645004632064
author Head, David R.
Jacobberger, James W.
Mosse, Claudio
Jagasia, Madan
Dupont, William
Goodman, Stacey
Flye, Leanne
Shinar, Andrew
McClintock-Treep, Sara
Stelzer, Greg
Briggs, Robert
Shults, Keith
author_facet Head, David R.
Jacobberger, James W.
Mosse, Claudio
Jagasia, Madan
Dupont, William
Goodman, Stacey
Flye, Leanne
Shinar, Andrew
McClintock-Treep, Sara
Stelzer, Greg
Briggs, Robert
Shults, Keith
author_sort Head, David R.
collection PubMed
description We used flow cytometry to analyze the cell cycle, DNA damage, and apoptosis in hematopoietic subsets in MDS marrow. Subsets were assigned using CD45, side scatter, CD34, and CD71. Cell cycle fractions were analyzed using DRAQ 5 (DNA content) and MPM-2 (mitoses). DNA damage was assessed using p-H2A.X, and apoptosis using Annexin V. Compared to controls, MDS patients demonstrated no increased mitoses in erythroid, myeloid, or CD34+ cells. Myeloid progenitors demonstrated increased G2 cells, which with no increased mitoses suggested delayed passage through G2. Myeloid progenitors demonstrated increased p-H2A.X, consistent with DNA damage causing this delay. Annexin V reactivity was equivalent in MDS and controls. Results for each parameter varied among hematopoietic compartments, demonstrating the need to analyze compartments separately. Our results suggest that peripheral cytopenias in MDS are due to delayed cell cycle passage of marrow progenitors and that this delayed passage and leukemic progression derive from excessive DNA damage.
format Online
Article
Text
id pubmed-3200066
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-32000662011-11-01 Innovative Analyses Support a Role for DNA Damage and an Aberrant Cell Cycle in Myelodysplastic Syndrome Pathogenesis Head, David R. Jacobberger, James W. Mosse, Claudio Jagasia, Madan Dupont, William Goodman, Stacey Flye, Leanne Shinar, Andrew McClintock-Treep, Sara Stelzer, Greg Briggs, Robert Shults, Keith Bone Marrow Res Research Article We used flow cytometry to analyze the cell cycle, DNA damage, and apoptosis in hematopoietic subsets in MDS marrow. Subsets were assigned using CD45, side scatter, CD34, and CD71. Cell cycle fractions were analyzed using DRAQ 5 (DNA content) and MPM-2 (mitoses). DNA damage was assessed using p-H2A.X, and apoptosis using Annexin V. Compared to controls, MDS patients demonstrated no increased mitoses in erythroid, myeloid, or CD34+ cells. Myeloid progenitors demonstrated increased G2 cells, which with no increased mitoses suggested delayed passage through G2. Myeloid progenitors demonstrated increased p-H2A.X, consistent with DNA damage causing this delay. Annexin V reactivity was equivalent in MDS and controls. Results for each parameter varied among hematopoietic compartments, demonstrating the need to analyze compartments separately. Our results suggest that peripheral cytopenias in MDS are due to delayed cell cycle passage of marrow progenitors and that this delayed passage and leukemic progression derive from excessive DNA damage. Hindawi Publishing Corporation 2011 2011-06-07 /pmc/articles/PMC3200066/ /pubmed/22046573 http://dx.doi.org/10.1155/2011/950934 Text en Copyright © 2011 David R. Head et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Head, David R.
Jacobberger, James W.
Mosse, Claudio
Jagasia, Madan
Dupont, William
Goodman, Stacey
Flye, Leanne
Shinar, Andrew
McClintock-Treep, Sara
Stelzer, Greg
Briggs, Robert
Shults, Keith
Innovative Analyses Support a Role for DNA Damage and an Aberrant Cell Cycle in Myelodysplastic Syndrome Pathogenesis
title Innovative Analyses Support a Role for DNA Damage and an Aberrant Cell Cycle in Myelodysplastic Syndrome Pathogenesis
title_full Innovative Analyses Support a Role for DNA Damage and an Aberrant Cell Cycle in Myelodysplastic Syndrome Pathogenesis
title_fullStr Innovative Analyses Support a Role for DNA Damage and an Aberrant Cell Cycle in Myelodysplastic Syndrome Pathogenesis
title_full_unstemmed Innovative Analyses Support a Role for DNA Damage and an Aberrant Cell Cycle in Myelodysplastic Syndrome Pathogenesis
title_short Innovative Analyses Support a Role for DNA Damage and an Aberrant Cell Cycle in Myelodysplastic Syndrome Pathogenesis
title_sort innovative analyses support a role for dna damage and an aberrant cell cycle in myelodysplastic syndrome pathogenesis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3200066/
https://www.ncbi.nlm.nih.gov/pubmed/22046573
http://dx.doi.org/10.1155/2011/950934
work_keys_str_mv AT headdavidr innovativeanalysessupportarolefordnadamageandanaberrantcellcycleinmyelodysplasticsyndromepathogenesis
AT jacobbergerjamesw innovativeanalysessupportarolefordnadamageandanaberrantcellcycleinmyelodysplasticsyndromepathogenesis
AT mosseclaudio innovativeanalysessupportarolefordnadamageandanaberrantcellcycleinmyelodysplasticsyndromepathogenesis
AT jagasiamadan innovativeanalysessupportarolefordnadamageandanaberrantcellcycleinmyelodysplasticsyndromepathogenesis
AT dupontwilliam innovativeanalysessupportarolefordnadamageandanaberrantcellcycleinmyelodysplasticsyndromepathogenesis
AT goodmanstacey innovativeanalysessupportarolefordnadamageandanaberrantcellcycleinmyelodysplasticsyndromepathogenesis
AT flyeleanne innovativeanalysessupportarolefordnadamageandanaberrantcellcycleinmyelodysplasticsyndromepathogenesis
AT shinarandrew innovativeanalysessupportarolefordnadamageandanaberrantcellcycleinmyelodysplasticsyndromepathogenesis
AT mcclintocktreepsara innovativeanalysessupportarolefordnadamageandanaberrantcellcycleinmyelodysplasticsyndromepathogenesis
AT stelzergreg innovativeanalysessupportarolefordnadamageandanaberrantcellcycleinmyelodysplasticsyndromepathogenesis
AT briggsrobert innovativeanalysessupportarolefordnadamageandanaberrantcellcycleinmyelodysplasticsyndromepathogenesis
AT shultskeith innovativeanalysessupportarolefordnadamageandanaberrantcellcycleinmyelodysplasticsyndromepathogenesis